We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 21, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lowe's Companies, Inc. (LOW - Free Report) , Gilead Sciences, Inc. (GILD - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) , Valero Energy Corp. (VLO - Free Report) and MercadoLibre, Inc. (MELI - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Lowe's, Gilead Sciences and Intuitive Surgical
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Lowe's Companies, Inc. Gilead Sciences, Inc. and Intuitive Surgical, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Lowe's shares have outperformed the Zacks Building Poducts - Retail industry over the past six months (+10.9% vs. +8.7%). The company remains well positioned to capitalize on demand for the home improvement market, backed by investments in technology, merchandise category and strength in Pro business.
Lowe's posted sturdy quarterly results wherein the bottom line beat the Zacks Consensus Estimate and grew year over year. Earnings performance benefited from strong operating margin, stemming from gains from the Total Home strategy and the execution of the Perpetual Productivity Improvement initiative. Focus on driving productivity boosted margins.
The Total Home strategy is resonating well with Pro and DIY customers for a while. Management is committed to enhancing the Pro offerings, expanding the company's market share and driving its operating margin.
Shares of Gilead Sciences have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+21.7% vs. -24.0%). The company's results are driven by continued demand for its HIV portfolio with further share growth for flagship therapy Biktarvy and oncology revenues driven by cell therapy and Trodelvy. Though sales of COVID-19 treatment, Veklury (remdesivir) declined, but came in better than expected.
The approval of new treatments like Sunlenca will strengthen the HIV franchise. The company is also looking to solidify its oncology franchise through internal pipeline development and strategic collaborations. The acquisition of Immunomedics added the breast cancer drug Trodelvy to its portfolio.
However, the loss of Atripla and Truvada's exclusivity is affecting sales. Although the CAR-T cell therapy franchise is gaining traction, it has a long way to go.
Intuitive Surgical's shares have declined -25.2% over the past year against the Zacks Medical - Instruments industry's decline of -29.4%. The company is facing macroeconomic and geopolitical headwinds that might significantly hurt small businesses operations, thereby posing risks for Intuit's top-line growth. Additionally, higher costs and expenses due to increased investments in marketing and engineering teams are likely to continue impacting bottom-line results in the near term.
However, Intuit is benefiting from strong momentum in online ecosystem revenues and solid professional tax revenues. The TurboTax Live offering is also driving growth in the Consumer tax business. Solid momentum in the company's lending product, QuickBooks Capital, remains a positive.
Moreover, the company's strategy of shifting its business to cloud-based subscription model will help generate stable revenues over the long run. We expect Intuit's revenues to grow at a CAGR of 13.2% through fiscal 2023-2025.
Other noteworthy reports we are featuring today include Valero Energy Corp. and MercadoLibre, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre
For Immediate Release
Chicago, IL – November 21, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lowe's Companies, Inc. (LOW - Free Report) , Gilead Sciences, Inc. (GILD - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) , Valero Energy Corp. (VLO - Free Report) and MercadoLibre, Inc. (MELI - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Lowe's, Gilead Sciences and Intuitive Surgical
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Lowe's Companies, Inc. Gilead Sciences, Inc. and Intuitive Surgical, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Lowe's shares have outperformed the Zacks Building Poducts - Retail industry over the past six months (+10.9% vs. +8.7%). The company remains well positioned to capitalize on demand for the home improvement market, backed by investments in technology, merchandise category and strength in Pro business.
Lowe's posted sturdy quarterly results wherein the bottom line beat the Zacks Consensus Estimate and grew year over year. Earnings performance benefited from strong operating margin, stemming from gains from the Total Home strategy and the execution of the Perpetual Productivity Improvement initiative. Focus on driving productivity boosted margins.
The Total Home strategy is resonating well with Pro and DIY customers for a while. Management is committed to enhancing the Pro offerings, expanding the company's market share and driving its operating margin.
(You can read the full research report on Lowe's here >>>)
Shares of Gilead Sciences have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+21.7% vs. -24.0%). The company's results are driven by continued demand for its HIV portfolio with further share growth for flagship therapy Biktarvy and oncology revenues driven by cell therapy and Trodelvy. Though sales of COVID-19 treatment, Veklury (remdesivir) declined, but came in better than expected.
The approval of new treatments like Sunlenca will strengthen the HIV franchise. The company is also looking to solidify its oncology franchise through internal pipeline development and strategic collaborations. The acquisition of Immunomedics added the breast cancer drug Trodelvy to its portfolio.
However, the loss of Atripla and Truvada's exclusivity is affecting sales. Although the CAR-T cell therapy franchise is gaining traction, it has a long way to go.
(You can read the full research report on Gilead Sciences here >>>)
Intuitive Surgical's shares have declined -25.2% over the past year against the Zacks Medical - Instruments industry's decline of -29.4%. The company is facing macroeconomic and geopolitical headwinds that might significantly hurt small businesses operations, thereby posing risks for Intuit's top-line growth. Additionally, higher costs and expenses due to increased investments in marketing and engineering teams are likely to continue impacting bottom-line results in the near term.
However, Intuit is benefiting from strong momentum in online ecosystem revenues and solid professional tax revenues. The TurboTax Live offering is also driving growth in the Consumer tax business. Solid momentum in the company's lending product, QuickBooks Capital, remains a positive.
Moreover, the company's strategy of shifting its business to cloud-based subscription model will help generate stable revenues over the long run. We expect Intuit's revenues to grow at a CAGR of 13.2% through fiscal 2023-2025.
(You can read the full research report on Intuitive Surgical here >>>)
Other noteworthy reports we are featuring today include Valero Energy Corp. and MercadoLibre, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.